GlobeNewswire by notified

SKEL fjárfestingafélag hf.: Buy-back programme week 38

Share

In week 38 2023, SKEL fjárfestingafélag hf. purchased in total 8,100,000 own shares for total amount of 103,255,000 ISK as follows:

DateTimePurchased sharesPricePurchase priceTotal own shares
18.9.202310:151,500,00012.10018,150,00020,018,518
19.9.202309:431,600,00012.40019,840,00021,618,518
20.9.202309:381,000,00013.10013,100,00022,618,518
20.9.202312:05750,00013.1009,825,00023,368,518
21.9.202310:051,000,00012.80012,800,00024,368,518
21.9.202315:01800,00013.00010,400,00025,168,518
22.9.202309:35500,00013.2006,600,00025,668,518
22.9.202309:35500,00013.2006,600,00026,168,518
22.9.202311:02450,00013.2005,940,00026,618,518
8,100,000103.255.00026.618.518

The execution of the buy-back programme is in accordance with Chapter VIII of the Company Act No 2/1995, Article 5 of the Regulation of the European parliament and of the Council (EU) on Market Fraud No. 60/2021, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021.

Before the purchase SKEL held 18,518,518 own shares. SKEL fjárfestingafélag hf. bought in total 8,100,000 own shares, which corresponds to 4.18% of maximum number of shares that will be purchased according to the current buy-back programme. The purchase price of the own shares is 103,255,000, or 20.65% of the maximum buy-back amount. SKEL now owns a total of 1.33% of the company's total share capital, which is 1,936,033,774. This announcement of purchase of own shares is in accordance with the buy-back programme announced 15 September 2023 to Nasdaq OMX Iceland.

For further information contact Magnús Ingi Einarsson, CFO of SKEL fjárfestingafélag hf., magnus@skel.is hf.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

LeddarTech and Prospector Capital Corp. Announce Effectiveness of Registration Statement and December 13, 2023 Extraordinary General Meeting to Approve Business Combination4.12.2023 23:30:00 CET | Press release

QUEBEC CITY, Dec. 04, 2023 (GLOBE NEWSWIRE) -- LeddarTech Inc.® (“LeddarTech” or the “Company”), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology for ADAS and AD, and Prospector Capital Corp. (“Prospector”) (NASDAQ: PRSR, PRSRU, PRSRW), a publicly traded special-purpose acquisition company led by former Qualcomm President Derek Aberle and chaired by former Qualcomm Vice Chairman Steve Altman, today announced that on December 4, 2023 the U.S. Securities and Exchange Commission (the “SEC”) declared effective the Registration Statement on Form F-4, as amended, filed by LeddarTech Holdings Inc. (“Newco”) in connection with the previously announced proposed business combination (the “Business Combination”). The filing can be viewed in its entirety on the SEC’s website at www.sec.gov. Prospector also commenced mailing the definitive proxy statement/prospectus on December 4, 2023, which was included in the Reg

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20234.12.2023 22:30:00 CET | Press release

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.4.12.2023 22:16:59 CET | Press release

Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount”, and the subscription transaction being the “Remaining Placement”), following the approval by the French Ministry of Economy of JJ

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH4.12.2023 22:05:00 CET | Press release

The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeksThe DMC review remains consistent, confirming the good safety profile of lanifibranor Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without modification to the trial protocol. The DMC

Standard Lithium to Participate in December Investor Conferences4.12.2023 22:04:35 CET | Press release

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences: Event:Deustche Bank 8th Annual Virtual Lithium Battery Supply Chain ConferenceDate:December 6, 2023Panel:US Based Lithium Supply, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:15am PTEvent:Bank of America Securities Virtual 2023 Lithium and Battery Storage ConferenceDate:December 7, 2023Panel:Company Presentation, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:30am PT Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their Deutsche Bank or Bank of America representative or Standard Lithium Investor Relations at investors@standardlithium.com. About Standard Lithium Ltd. St